Clay Siegall Setting pace in the Medical Scientific Research Field



With science growing daily, our knowledge about the natural world equally widens. Scientists are in a continuous process of developing new knowledge about existing phenomena. This paradigmatic shift in information and general knowledge is what tends to make us cope with real life changes. Clay Siegall is among the scientists who have delved in the field of natural science for a long period and, as such, his impact and influence has really initiated change in the world of health science. Siegall writes on scientific subjects, mainly on the recent developments and findings in the field of science.


Clay Siegall recently argued out his view on why most medical breakthroughs don’t actually materialize. Siegall established that almost half of the scientific findings in the medical field don’t see the light of day due to lack of deeper scrutiny. People tend to be overexcited about new findings that they fail to dig deep into the finer details of the case subject; thus, most of the findings don’t stand the test of time. He also blames this on journalists who are ever on the lookout for new findings, neglecting to report and shed light on earlier established knowledge. To this effect, most of the findings die a natural death. His recent writings on human anatomy and several disease study cases are among the works he is highly credited for.


Dr. Siegall co-founded Seattle Genetics back in 1998, tremendously seeing the growth of the company since then while acting both as the president and as the CEO of the company. The company is concerned with scientific innovations, rigorous research and drug development as well as patient treatments. His main responsibility has been guiding the organization to its successful position in coming up with antibody-drugs (ADCs) and in achieving the 2011 FDA approval of its first ever ADC product.


Siegall has over 20 years of experience in the Cancer Research and Therapeutic Drug Development, having worked with the National Cancer Institute prior to co-founding Seattle Genetics. He has also worked with the Bristol-Myers Squibb Pharmaceutical Research Institute. Working in these organizations has made him an experienced figure in the medical world.